Since we demonstrated that PRMT3 inhibitor sensitized HCC cell lines to OXA treatment, we examined the effect of PRMT3 inhibitor SGC707 on the responses of HCC PDCs to OXA. The gene discussed is PRMT3; the disease is hepatocellular carcinoma.